Seres Therapeutics, Inc.
NASDAQ:MCRBBiotechnology
+$0.11 today
- Market cap
- $51.13M
- Beta
- 0.11
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$4.89
Volume 0.04M
Average 0.06M
MCRB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Seres Therapeutics, Inc.NASDAQ: MCRB
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $13.2M rose 11.6% year over year, ahead of the -33.6% change in trailing-twelve-month research & development. Sequentially, it rose 12.9% from the prior quarter. Over 3 fiscal years it compounded at -23.5% a year.
Context
- Research & development amounted to 6218.0% of revenue in FY2025.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +11.6% holds above the trailing-twelve-month pace of -33.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 49.06M USD
- Year-over-year change
- -24.1%
- 4-year CAGR
- -23.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.06M | -24.1% |
| FY2024 | 2024-12-31 | 64.6M | -45.1% |
| FY2023 | 2023-12-31 | 117.6M | +7.2% |
| FY2022 | 2022-12-31 | 109.65M | -22.7% |
| FY2021 | 2021-12-31 | 141.89M | — |
Research & Development vs competitors
How MCRB compares with its peers on the latest reported figures
- MCRB's LTM Mar 2026 research & development of $37.82M is the 4th highest of the 9 companies compared; the peer median is $32.94M.
- Its year-over-year change of -33.6% is the 7th highest of 9, against a peer median of -16.9%.
- Research & development amounts to 3297.1% of revenue for MCRB, versus a peer median of 274.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $96.1M | -9.9% | +48.0% | — | |
| LTM Mar 2026 | $51.51M | -27.2% | -33.9% | — | |
| LTM Mar 2026 | $41.33M | -11.2% | -6.2% | 274.8% | |
| LTM Mar 2026 | $37.82M | -33.6% | -23.5% | 3297.1% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $33.44M | +11.2% | +29.0% | 279.0% |
| LTM Mar 2026 | $32.45M | -22.6% | +7.0% | — | |
| LTM Mar 2026 | $27.77M | -70.1% | -6.9% | 50.7% | |
| LTM Mar 2026 | $21.18M | +82.5% | +30.2% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $9.64M | -35.9% | -14.4% | — |
| Peer median (excluding MCRB) | $32.94M | -16.9% | +0.4% | 274.8% | |
Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 144.93M | 0 | 0 | 0 | 789K |
| Cost of Revenue | 0 | 0 | 19.34M | 3.53M | 4.13M |
| Gross Profit | 144.93M | 0 | (19.34M) | (3.53M) | (3.34M) |
| Gross Margin | 100.0% | — | — | — | -423.8% |
| Research & Development | 141.89M | 109.65M | 117.6M | 64.6M | 49.06M |
| Selling, General & Admin | 69.26M | 70.26M | 77.5M | 53.18M | 39.16M |
| Operating Expenses | 209.42M | 179.91M | 175.76M | 117.78M | 90.63M |
| Depreciation & Amortization | 5.95M | 6.63M | 6.24M | 5.47M | 4.13M |
| EBITDA | (56.72M) | (170.93M) | (181.42M) | (120.3M) | 9.83M |
| EBITDA Margin | -39.1% | — | — | — | 1245.8% |
| Operating Income | (64.49M) | (179.91M) | (195.1M) | (121.32M) | (93.97M) |
| Operating Margin | -44.5% | — | — | — | -11910.1% |
| Interest Income | 2.87M | 3.06M | 7.3M | 3.97M | 2.23M |
| Interest Expense | 2.91M | 6.02M | 13.18M | 0 | 0 |
| Other Income / Expenses | (1.09M) | (3.67M) | 4.97M | (4.46M) | 99.67M |
| Income Before Tax | (65.58M) | (183.58M) | (190.13M) | (125.77M) | 5.7M |
| Pre-Tax Margin | -45.2% | — | — | — | 721.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (65.58M) | (250.16M) | (113.72M) | (146.57M) | 5.7M |
| Net Margin | -45.2% | — | — | — | 721.9% |
| EPS (Basic) | (14.30) | (46.29) | (17.77) | (18.86) | 0.64 |
| EPS (Diluted) | (14.30) | (46.29) | (17.77) | (18.86) | 0.64 |
| Weighted Avg Shares | 4.59M | 5.4M | 6.4M | 7.77M | 8.86M |
| Weighted Avg Shares (Diluted) | 4.59M | 5.4M | 6.4M | 7.77M | 8.87M |
Seres Therapeutics, Inc.
NASDAQ:MCRB
Intrinsic Alpha fair value
Locked
Current Price
$5.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.